The inter-relationship between various non-motor symptoms and with habitual physical activity in Parkinsonism: a scoping review protocol

References

• Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–1601.
   PubMed Web of Science ®Google Scholar
• Litvan I. Atypical Parkinsonian disorders clinical and research aspects. Totowa, NJ: Humana Press: Imprint: Humana; 2005.
   Google Scholar
• Horvath J, Burkhard PR, Bouras C, et al. Etiologies of Parkinsonism in a century‐long autopsy‐based cohort. Brain Pathol. 2013;23(1):28–33.
   PubMed Web of Science ®Google Scholar
• Litvan I, Bhatia KP, Burn DJ, Movement Disorders Society Scientific Issues Committee, et al. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18(5):467–486.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–953.
   PubMed Web of Science ®Google Scholar
• Rossi A, Berger K, Chen H, et al. Projection of the prevalence of Parkinson’s disease in the coming decades: revisited. Mov Disord. 2018;33(1):156–159.
   PubMed Web of Science ®Google Scholar
• Levin J, Kurz A, Arzberger T, et al. The differential diagnosis and treatment of atypical Parkinsonism. Dtsch Arztebl Int. 2016;113(5):61–69.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essential. Curr Neurol Neurosci Rep. 2005;5(4):275–283.
   PubMedGoogle Scholar
• Weintraub D, Burn DJ. Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord. 2011;26(6):1022–1031.
   PubMed Web of Science ®Google Scholar
• Colosimo C, Morgante L, Antonini A, PRIAMO STUDY GROUP, et al. Non-motor symptoms in atypical and secondary Parkinsonism: the PRIAMO study. J Neurol. 2010;257(1):5–14.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Odin P, Antonini A, et al. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17(10):717–723.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre‐motor disorders in Parkinson’s disease. Mov Disord. 2012;27(5):617–626.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, PRIAMO study group, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649.
   PubMed Web of Science ®Google Scholar
• Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2011;17(1):1–9.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, NMSS Validation Group, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406.
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–312.
   PubMed Web of Science ®Google Scholar
• Braak H, Tredici KD, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Trojanowski J, Revesz T, MSA NWGo. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. 2007;33(6):615–620.
   PubMed Web of Science ®Google Scholar
• Zgaljardic D, Foldi N, Borod J. Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm (Vienna). 2004;111(10–11):1287–1301.
   PubMed Web of Science ®Google Scholar
• Tekin S, Cummings JL. Frontal–subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res. 2002;53(2):647–654.
   PubMed Web of Science ®Google Scholar
• Lewis SJG, Barker RA. A pathophysiological model of freezing of gait in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(5):333–338.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AHV, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–99.
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10):1468–1474.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Sullivan K, Arnulf I, Quality Standards Subcommittee of the American Academy of Neurology, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the quality standards subcommittee of the American academy of neurology. Neurology. 2010;74(11):924–931.
   PubMed Web of Science ®Google Scholar
• Giagkou N, Stamelou M. Therapeutic management of the overlapping syndromes of atypical Parkinsonism. CNS Drugs. 2018;32(9):827–837.
   PubMed Web of Science ®Google Scholar
• Engels G, Douw L, Kerst Y, et al. Non-motor symptoms in Parkinson’s disease: an explorative network study. Parkinsonism Relat Disord. 2019;66:237–240.
   PubMed Web of Science ®Google Scholar
• Feliciano JS, Rodrigues SMA, de Carvalho Lana R, et al. Predictors of physical activity levels in individuals with Parkinson’s disease: a cross-sectional study. Neurol Sci. 2020;42:1499–1505.
   PubMed Web of Science ®Google Scholar
• Afshari M, Yang A, Bega D. Motivators and barriers to exercise in Parkinson’s disease. JPD. 2017;7(4):703–711.
   Google Scholar
• Ellis T, Cavanaugh JT, Earhart GM, et al. Factors associated with exercise behavior in people with Parkinson disease. Phys Ther. 2011;91(12):1838–1848.
   PubMed Web of Science ®Google Scholar
• Ellis T, Boudreau JK, DeAngelis TR, et al. Barriers to exercise in people with Parkinson disease. Phys Ther. 2013;93(5):628–636.
   PubMed Web of Science ®Google Scholar
• Cusso ME, Donald KJ, Khoo TK. The impact of physical activity on non-motor symptoms in Parkinson’s disease: a systematic review. Front Med (Lausanne). 2016;3:35–35.
   PubMed Web of Science ®Google Scholar
• Murray DK, Sacheli MA, Eng JJ, et al. The effects of exercise on cognition in Parkinson’s disease: a systematic review. Transl Neurodegener. 2014;3(1):5–13.
   PubMedGoogle Scholar
• Cristini J, Weiss M, De Las Heras B, et al. The effects of exercise on sleep quality in persons with Parkinson’s disease: a systematic review with meta-analysis. Sleep Med Rev. 2021;55:101384.
   PubMed Web of Science ®Google Scholar
• Qureshi AR, Jamal MK, Rahman E, et al. Non‐pharmacological therapies for pain management in Parkinson’s disease: a systematic review. Acta Neurol Scand. 2021;144(2):115–131.
   PubMed Web of Science ®Google Scholar
• Lin I, Edison B, Mantri S, et al. Triggers and alleviating factors for fatigue in Parkinson’s disease. PLoS ONE. 2021;16(2):e0245285.
   PubMed Web of Science ®Google Scholar
• Elbers RG, Verhoef J, van Wegen EEH, et al. Interventions for fatigue in Parkinson’s disease. Cochrane Database Syst Rev. 2015;(10):CD010925. https://doi.org/10.1002/14651858.CD010925.pub2.
   Google Scholar
• Emig M, George T, Zhang JK, et al. The role of exercise in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2021;34(4):321–330.
   PubMed Web of Science ®Google Scholar
• Speelman AD, Van De Warrenburg BP, Van Nimwegen M, et al. How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol. 2011;7(9):528–534.
   PubMed Web of Science ®Google Scholar
• Yi-Chen C, Chun-Hsien S. Evidence supports PA prescription for Parkinson’s disease: motor symptoms and non-motor features: a scoping review. IJERPH. 2020;17(8):2894.
   Google Scholar
• van Nimwegen M, Speelman AD, Hofman-van Rossum EJM, et al. Physical inactivity in Parkinson’s disease. J Neurol. 2011;258(12):2214–2221.
   PubMed Web of Science ®Google Scholar
• Cavanaugh JT, Ellis TD, Earhart GM, et al. Toward understanding ambulatory activity decline in Parkinson disease. Phys Ther. 2015;95(8):1142–1150.
   PubMed Web of Science ®Google Scholar
• Kim H-S, Cheon S-M, Seo J-W, et al. Nonmotor symptoms more closely related to Parkinson’s disease: comparison with normal elderly. J Neurol Sci. 2013;324(1–2):70–73.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Sarma G, Sarma S, et al. Do nonmotor symptoms in Parkinson’s disease differ from normal aging? Mov Disord. 2011;26(11):2110–2113.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep. 1985;100(2):126–131.
   PubMed Web of Science ®Google Scholar
• Reuter I, Harder S, Engelhardt M, et al. The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa. Mov Disord. 2000;15(5):862–868.
   PubMed Web of Science ®Google Scholar
• Muhlack S, Welnic J, Woitalla D, et al. Exercise improves efficacy of levodopa in patients with Parkinson’s disease. Mov Disord. 2007;22(3):427–430.
   PubMed Web of Science ®Google Scholar
• Ouchi Y, Kanno T, Okada H, et al. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson’s disease. Brain. 2001;124(Pt 4):784–792.
   PubMedGoogle Scholar
• Stephenson R, Siderowf A, Stern MB. Premotor Parkinson’s disease: clinical features and detection strategies. Mov Disord. 2009;24(S2):S665–S670.
   PubMedGoogle Scholar
• Dishman RK, O'Connor PJ. Lessons in exercise neurobiology: the case of endorphins. Ment Health Phys Act. 2009;2(1):4–9.
   Google Scholar
• Kinsella KG, Phillips DR. Global aging: the challenge of success. Trade Journal. 2005;60(1):3–40.
   Google Scholar
• Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
   Google Scholar
• Peters MD, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119–2126.
   PubMedGoogle Scholar
• Shamseer L, Moher D, Clarke M, the PRISMA-P Group, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(jan02 1):g7647–g7647.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, PRISMA Group, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Lefebvre C, Glanville J, Briscoe S, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane; 2022. Available from: www.training.cochrane.org/handbook.
   Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7(1):1–6.
   PubMedGoogle Scholar
• Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane; 2022.
   Google Scholar
• Gilpin AR. Table for conversion of Kendall’S Tau to Spearman’S Rho within the context of measures of magnitude of effect for meta-analysis. Educ Psychol Meas. 1993;53(1):87–92.
   Web of Science ®Google Scholar
• Kan C, Silva N, Golden SH, et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36(2):480–489.
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):1–10.
   PubMedGoogle Scholar
• Moola S, Munn Z, Tufanaru C, et al. Chapter 7: systematic reviews of etiology and risk. Joanna Briggs Institute Reviewer’s Manual. The Joanna Briggs Institute; 2017.
   Google Scholar